Sign In
Buy VKTX
$32.37
+1.99 (+6.55%)
At Close: Jun 22, 2026
Why Viking Therapeutics Stock Is Up More Than 9% Today
12:43pm, Monday, 23'rd Feb 2026
Novo Nordisk's weight-loss drug CagriSema failed to meet a critical goal in late-stage clinical trials. This shortcoming bodes well for pharmaceutical companies working on similar obesity treatments.
3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds
05:10am, Monday, 23'rd Feb 2026
Viking Therapeutics aims to enter the billion-dollar weight loss drug market. The company is studying a candidate in a phase 3 trial.
2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street
06:10pm, Thursday, 19'th Feb 2026
Biotech companies could add growth to your portfolio -- and in some cases, at a bargain price. It's a great idea to select tomorrow's potential winners and hold on as their stories unfold.
Is Viking Therapeutics Stock Really Going to $125?
03:23pm, Thursday, 19'th Feb 2026
Viking Therapeutics is nearly done developing and testing a potential GLP-1 weight loss drug. While the company is still losing money, the underlying business appears solid.
2026 Could Be a Big Year for Viking Therapeutics. Time to Buy?
08:15am, Tuesday, 17'th Feb 2026
Viking should have plenty of news to share with investors this year.
Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year
09:40am, Monday, 16'th Feb 2026
Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%.
Viking Therapeutics: Full-Speed Ahead
08:44am, Saturday, 14'th Feb 2026
Viking Therapeutics is aggressively advancing its GLP-1 pipeline, with two pivotal Phase 3 trials now underway or imminent. VKTX's Phase 2 oral data showed up to 14.7% weight loss in 13 weeks, positio
Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market
11:26am, Friday, 13'th Feb 2026
/PRNewswire/ -- Equity-Insider.com News Commentary - The global health and wellness sector is entering 2026 on a trajectory toward $6 trillion in annual
Viking Therapeutics: Buyers Are Quietly Accumulating On Its Obesity Drugs Launch Potential
08:35am, Friday, 13'th Feb 2026
Viking Therapeutics is still kept as a speculative buy, with selling pressure subsiding and constructive consolidation signaling renewed investor interest. VKTX's dual-track pipeline and manufacturing
VKTX Posts Wider-Than-Expected Loss in Q4, Stock Up on Pipeline Updates
09:06am, Thursday, 12'th Feb 2026
Viking Therapeutics posts a wider-than-expected Q4 loss, but shares jump as it advances oral VK2735 into late-stage obesity studies.
Viking Therapeutics, Inc. (VKTX) Q4 2025 Earnings Call Transcript
12:44am, Thursday, 12'th Feb 2026
Viking Therapeutics, Inc. (VKTX) Q4 2025 Earnings Call Transcript
Viking Therapeutics plans to advance oral obesity drug to late-stage trial
05:10pm, Wednesday, 11'th Feb 2026
Viking Therapeutics said on Wednesday that it plans to test its experimental oral obesity drug in a late-stage study later this year.
Viking Therapeutics Stock Climbs After Q4 Report: Details
04:33pm, Wednesday, 11'th Feb 2026
Here's a look at the key figures from the quarter.
Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
04:16pm, Wednesday, 11'th Feb 2026
Conference call scheduled for 4:30 p.m. ET today Oral VK2735 to Advance into Phase 3 for Obesity in 3Q26 Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Ongoing; VANQUISH-1 Enrollment Compl
Breakfast News: First SaaS, Now Finance Hit By AI
07:30am, Wednesday, 11'th Feb 2026
AI makes move into tax planning, Shopify and Unity report this morning, and more
